Education and comparison only — nothing here prescribes, orders, or books anything. Supplements get their real evidence grade, not an upgraded one.
Hot flashes are a well-established, directly menopause-linked symptom, supported by guideline-level evidence and decades of hormone and nonhormone therapy trials.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Systemic estrogen therapy (± progestogen)
Oral, transdermal, or other systemic estrogen, combined with a progestogen for women with a uterus. Treats vasomotor symptoms and genitourinary symptoms body-wide.
Systemic estrogen therapy remains the most effective treatment for moderate-to-severe vasomotor symptoms in appropriate candidates, per NAMS's 2022 position statement.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Low-dose vaginal estrogen
Low-dose estrogen applied locally (cream, tablet, or ring) to treat vaginal dryness and related genitourinary symptoms, with minimal systemic absorption.
Low-dose vaginal estrogen is a well-established, effective treatment for genitourinary syndrome of menopause, with a strong safety profile due to minimal systemic absorption.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Fezolinetant
A once-daily oral NK3 receptor antagonist, FDA-approved specifically for moderate-to-severe vasomotor symptoms. Requires liver-function monitoring per FDA safety guidance.
Fezolinetant is FDA-approved (2023) for vasomotor symptoms with strong RCT evidence (Level I per NAMS), though it has not been directly compared to hormone therapy in head-to-head trials, and carries a rare but serious liver-injury warning requiring monitoring.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Low-dose paroxetine / SSRIs / SNRIs
Low-dose paroxetine (7.5mg) is FDA-approved specifically for vasomotor symptoms; other SSRIs/SNRIs (e.g., venlafaxine) are used off-label for the same purpose.
Low-dose paroxetine and related SSRIs/SNRIs have Level I evidence (per NAMS) for reducing vasomotor symptom frequency and severity.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Gabapentin
An anti-seizure medication used off-label for vasomotor symptoms, typically dosed 900-2,400mg/day in divided doses.
Gabapentin has Level I evidence (per NAMS) for improving vasomotor symptom frequency and severity, with one trial finding high-dose gabapentin comparable to low-dose estrogen for symptom severity, at the cost of more side effects (dizziness, disorientation).
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Cognitive behavioral therapy (CBT)
A structured talk therapy that helps reframe how bothersome vasomotor symptoms feel, and separately supports sleep and mood during the transition.
CBT has Level I evidence (per NAMS) for reducing how bothersome vasomotor symptoms feel, with 65-78% of women in trials reaching clinically meaningful improvement; supporting evidence for sleep and mood benefits is real but comes from smaller, secondary analyses.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Black cohosh
An herbal supplement commonly marketed for hot flashes.
Evidence on black cohosh for hot flashes is mixed. A 2012 Cochrane review of 16 trials (2,027 women) found no clear benefit over placebo, while a 2023 meta-analysis of 22 trials (2,310 women), including black cohosh combined with other ingredients, found a small improvement in hot flashes and overall menopause symptoms, but not in anxiety or low mood. Studies used different extracts and doses, so a result from one product may not apply to another, and the Menopause Society does not recommend herbal remedies as an established treatment for hot flashes.
Early, limited, mixed, or indirect research. Some people may find this useful, but we can't be confident about the average effect.
What does this grade mean?Soy isoflavones / phytoestrogens
Plant-derived compounds structurally similar to estrogen, taken as food or supplements for vasomotor symptoms.
Evidence on soy isoflavones is mixed. A 2025 meta-analysis of 12 studies found a small improvement in overall menopause symptoms but no significant effect on hot flashes, sweating, or other vasomotor symptoms, and the Menopause Society does not recommend soy foods, soy extracts, or the soy metabolite equol for hot flashes. A 2019 meta-analysis of small trials found that equol supplements lowered hot-flash scores in women who don't naturally produce equol, but that is too limited to predict who will benefit or to recommend a product.
Early, limited, mixed, or indirect research. Some people may find this useful, but we can't be confident about the average effect.
What does this grade mean?